Introduction In 2003, erastin, a novel compound was identified, which showed a selective lethality against human foreskin cells (BJeLR cells) expressing engineered mutated RAS oncogene while using high-throughput screening to find out 23,550 compounds for their ability to eliminate engineered tumorigenic cells (Dolma et al., 2003)
Assumption of Responsibility The purchaser is responsible for evaluating product suitability for a proposed lawful research protocol and for all risks arising from possession, handling, storage, experimental use, transfer, and disposal
No dose-dependent increase in adverse events was observed, and no serious adverse events were attributed to the drug
This can include irregular bleeding, spotting between periods, heavier or lighter flow, or even the absence of periods altogether
Exact protocols vary
CD155 (poliovirus receptor) is frequently overexpressed on osteosarcoma cells and interacts with TIGIT expressed on infiltrating cytotoxic T cells and natural killer (NK) cells
